melanoma

gold arrow pointing upward forward
Biotech

Replimune's stock spikes 100% on FDA acceptance of resubmission

The FDA expects to make an approval decision on or before April 10, according to Replimune.
Gabrielle Masson Oct 20, 2025 5:33pm
BioNTech

BioNTech fades cancer vax in late-stage melanoma setting

Oct 20, 2025 3:01pm
vials vaccine research vaccines factory manufacturing

Evaxion stock slips on phase 2 cancer vax data

Oct 17, 2025 2:07pm
green light go go ahead advance yes streetlight

Moderna posts melanoma data behind decision to say 'I do' to IDO

Oct 13, 2025 5:15am
Layoffs

IO lays off 50% after FDA derails cancer vaccine approval plan

Sep 29, 2025 8:55am
dominoes fall series fail

Krystal discontinues melanoma study after FDA's Replimune rebuff

Aug 21, 2025 10:50am